---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011626"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:06:05.220180+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Hookipa reports Q2 net loss $19.1M; cash $77.4M; eseba-vec Phase 2/3 trial on track for Q4 2024

## Summary
- Net loss of $19.1M for Q2 2024 vs $18.0M in Q2 2023; revenue $1.3M down from $2.7M.
- Cash, cash equivalents and restricted cash fell to $77.4M from $117.5M as of Dec 31, 2023.
- Malte Peters appointed CEO and Terry Coelho as EVP & CFO effective July 22, 2024.
- Eseba-vec (HB-200) AVALON-1 Phase 2/3 trial aligned with FDA; start expected Q4 2024.
- Received $5M milestone from Gilead for HB-500 HIV Phase 1b first dosing; $10M from Roche for HB-700 IND.

## SEC filing metadata
- accession: 0001558370-24-011626
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000155837024011626/0001558370-24-011626-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000155837024011626/hook-20240808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011626
- JSON: https://secwatch.observer/filing/0001558370-24-011626.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011626.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.